Hexarelin
- Status
- Phase 2, , not approved for human use
- Evidence
Small human trials, body composition unchanged, graded on the Peptides for Muscle Growth bench
Hexarelin (also called examorelin) is a potent synthetic hexapeptide growth hormone secretagogue with the sequence His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2.
Reviewed
01Overview
What Hexarelin is
It is structurally similar to GHRP-6 and GHRP-2 but features a 2-methyl-substituted tryptophan residue. In young adults, intravenous hexarelin released about as much GH as GHRP-2 at the same doses, and more than GHRH (Arvat et al., 1997).
Read the full overviewShow less
Hexarelin also raises cortisol, prolactin and ACTH: a 2 mcg/kg intravenous dose raised all three significantly in 12 healthy volunteers (Korbonits et al., 1995). That is not unique among the classical GHRPs: in the head-to-head studies, GHRP-2 at the same intravenous doses raised cortisol, ACTH and prolactin to levels similar to those after hexarelin (Arvat et al., 1997; Arvat et al., 1999). Chronic twice-daily use partly blunts the GH response (significantly lower at weeks 4 and 16 of a 16-week trial and back to baseline 4 weeks after stopping, Rahim et al., 1998; no study has compared this blunting with other GHRPs), making hexarelin better suited to short aggressive cycles than to continuous long-term protocols.
Beyond its GH-axis effects, hexarelin has generated significant research interest for cardioprotective properties mediated through CD36 receptor binding — a mechanism independent of GHS-R1a. Preclinical studies have documented reduced infarct size following ischemia-reperfusion insult, improved cardiac contractility, and beneficial effects on cardiac remodeling in animal models ([Torsello et al., 2003]). Clinical translation to human cardiac therapy has not occurred, but the cardiac research niche distinguishes hexarelin from other GHRPs.
Hexarelin has been studied extensively in clinical trials for pediatric and adult GH deficiency diagnostic testing, particularly in European centers, where single IV boluses produce reliable and discriminating GH responses ([Loche et al., 1995]; [Arvat et al., 1995]). It is not FDA-approved and has no broadly approved therapeutic indication. Research-grade use is via SC injection, typically 100-200 mcg 1-3 times daily, with shorter cycling (4-6 weeks on / 2-4 weeks off) more commonly recommended than with other GHRPs because repeated twice-daily use partly blunts the growth hormone response.
How it works
Dual Receptor Pharmacology
Hexarelin is distinguished from other GHRPs by its activity at two distinct receptors:
GHS-R1a (primary - GH release)
Like all GHRPs, hexarelin binds the ghrelin receptor (GHS-R1a) on pituitary somatotrophs and hypothalamic neurons:
- Gq/11 coupling phospholipase C IP3/Ca release GH granule exocytosis
- Hypothalamic arcuate nucleus activation endogenous GHRH amplification
- Partial somatostatin antagonism removes the GH-release ceiling
Read the full mechanismShow less
In young adults, hexarelin released about as much GH as GHRP-2 at the same intravenous doses, and more than GHRH (Arvat et al., 1997). Peak GH elevations of ~50-70 ng/mL are achievable with modest (1-2 mcg/kg) IV bolus doses.
CD36 (secondary - cardioprotective)
Hexarelin also binds CD36 - a scavenger receptor expressed on cardiomyocytes, macrophages, and vascular endothelium. CD36 binding is not a property of GHRP-2 or ipamorelin; it is a distinctive hexarelin feature and drives the cardioprotective effects:
- Reduced infarct size in experimental ischemia-reperfusion ([Torsello 2003])
- Improved ventricular contractility in cardiomyopathy models
- Anti-inflammatory effects at vascular endothelium
- Favorable cardiac remodeling following experimental MI
The CD36 pathway is mechanistically independent of the GH/IGF-1 axis - hexarelin produces cardiac protection even when co-administered with GHS-R1a antagonists that block the GH-release signal. This has generated ongoing research interest in ghrelin-agonist cardioprotection as a discrete therapeutic avenue.
HPA Axis Cross-Reactivity
Hexarelin also raises ACTH, cortisol and prolactin. In head-to-head studies in young adults, GHRP-2 at the same intravenous doses raised all three to similar levels (Arvat et al., 1997; Arvat et al., 1999); the ipamorelin column comes from conscious swine, not people (Raun et al., 1998):
| HPA Effect | Hexarelin | GHRP-2 | Ipamorelin |
|---|---|---|---|
| Cortisol elevation | Significant rise | Similar to hexarelin | No rise beyond GHRH (swine) |
| ACTH elevation | Significant rise | Similar to hexarelin | No rise beyond GHRH (swine) |
| Prolactin elevation | Significant rise | Similar to hexarelin | No change (swine) |
This is why hexarelin is poorly suited to chronic daily use and better suited to short aggressive cycles (4-6 weeks) where peak anabolic effect is prioritized and cumulative HPA exposure is limited.
GHS-R1a Desensitization
Chronic hexarelin administration partly blunts its own GH response. In a 16-week trial of twice-daily subcutaneous injections, the response was significantly lower at weeks 4 and 16 and returned to baseline 4 weeks after stopping (Rahim et al., 1998). Imbimbo 1994 gave single doses and did not test repeated use, and no study has compared this blunting with GHRP-2 or ipamorelin.
This pharmacodynamic quirk drives a shorter cycling recommendation - typically 4-6 weeks on with 2-4 weeks off, or a low-dose (<100 mcg) maintenance if continuous use is required.
Synergy with GHRH
Despite its selectivity issues, hexarelin retains the classical GHS x GHRH synergy. Given with GHRH in a single intravenous test, hexarelin released more GH than either peptide alone, and the interaction was synergistic in healthy men (Giustina et al., 1996); in 178 normal adults, GHRH plus 0.25 mcg/kg of hexarelin gave a mean peak GH of 86 ng/mL, against 55 ng/mL after 2 mcg/kg of hexarelin alone and 19 ng/mL after GHRH alone (Aimaretti et al., 2000).
The practical question with hexarelin+GHRH is whether the larger GH peak of the pair compensates for hexarelin's cortisol and prolactin rises. In short-duration anabolic phases, usually yes; in chronic protocols, usually no.
Appetite Effects
Hexarelin is intermediate in its appetite-stimulating effects - more than ipamorelin (which is minimal), less than GHRP-6 (which is pronounced), and roughly equivalent to GHRP-2.
Studied for
- GH deficiency
- Cardiac ischemia
- Heart failure
- Body composition
Benefits listed
- Maximum GH output
- Cardiac protection
- Muscle building
- Body composition
Show 1 moreShow less
- Recovery
02Research
Free with emailWhat the research shows
Graded on a research bench
Reference pages that put Hexarelin next to the compounds people pair it with: roles, evidence, overlap and conflicts. No dosing. Research use only.
Unlock the research summary
Enter your email to keep reading. It is free, and it opens these sections on every compound page in this browser.
- A summary of the key research
- Safety and side effects
- A link to the PubMed results
You also get the free peptide cheat sheet by email. Unsubscribe anytime.
Have an account? Sign in
03Safety
Hexarelin side effects and interactions
Side effects
Moderate riskStop use if
- Active malignancy
- Uncontrolled cardiovascular disease
- Cushing's syndrome
Common
- Cortisol and prolactin elevation
- Water retention
- Fatigue
- Hunger
Less common
- Rapid desensitization with continuous use
- Elevated blood pressure
Who should not use it
Contraindications
Hexarelin is contraindicated or requires strict caution in:
- Active malignancy — particularly hormone-responsive cancers; IGF-1 elevation theoretical risk
- Strong family history of GH-axis sensitive cancers — specialist supervision required
- Pregnancy and lactation — no established safety data
- Known hypersensitivity to hexarelin or related hexapeptides
- Severe untreated obstructive sleep apnea — stabilize with CPAP first
- Acute critical illness — GH-axis stimulation inappropriate during sepsis, post-surgical recovery, multiple trauma, respiratory failure
- Diabetic ketoacidosis or severe uncontrolled diabetes — resolve metabolic state first
- Active proliferative retinopathy — relative contraindication
- Hypothalamic-pituitary disease with untreated adrenal insufficiency — hexarelin's HPA effects may be unreliable in this context
- Active Cushing's syndrome or elevated baseline cortisol — hexarelin adds meaningfully to HPA load
- Prolactinoma or clinically significant hyperprolactinemia — hexarelin's prolactin elevation could complicate management
- Active anxiety disorder, panic disorder, or acute stress reaction — HPA axis effects can worsen symptoms
Read all the contraindications and cautionsShow less
Relative cautions specific to hexarelin:
- Borderline glucose / HbA1c — insulin sensitivity effects appear faster with hexarelin than with cleaner GHS compounds
- Mood instability, depression, or insomnia — the HPA axis effects may contribute to worsening
- Cardiovascular disease (despite preclinical CD36 data) — the acute blood pressure and cortisol effects are not neutral in this population; clinical cardiac use has not been validated
- Concurrent glucocorticoid therapy — pharmacodynamic interference; additive HPA load
- Strong family history of colon polyps — baseline colonoscopy before GH-axis intervention
- Users who have had previous difficulty tolerating GHS compounds — hexarelin raises ACTH, cortisol and prolactin about as much as GHRP-2 at the same dose (PMID 10195374), and the evidence that ipamorelin spares these hormones comes only from swine (PMID 9849822)
Drug interactions:
- Glucocorticoids: Reduced GH response; additive HPA load
- Stimulants (high caffeine, pre-workouts): Additive sympathomimetic and HPA load
- MAO inhibitors: Theoretical interaction; specialist oversight
- GLP-1 agonists during weight loss phase: Opposing appetite signals
- Thyroid hormones: GH-axis effects can alter thyroid needs
- Exogenous HGH: Pharmacologically counterproductive
Discontinuation triggers:
- Cortisol elevation >30% above baseline at follow-up labs
- ACTH elevation beyond reference range
- Prolactin elevation beyond reference range
- New or worsened anxiety, insomnia, or mood changes
- Fasting glucose persistently >110 mg/dL
- Central (abdominal) weight gain beyond caloric intake explanation — suggesting cortisol-driven body composition change
- Persistent joint pain or peripheral edema
- Worsening sleep apnea
- Any cardiovascular symptoms
Interactions
3 pairings in our record: 1 with a caution and 2 noted as compatible or synergistic. Compatible and synergistic are notes from the record, not safety findings.
Ipamorelin
CautionBoth are GHRPs — generally choose one
CJC-1295
SynergisticGHRP + GHRH for amplified GH pulse
MK-677
CompatibleDifferent administration routes, can complement each other
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
Need bloodwork before starting?
Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount.
04Dosing
Free with emailHexarelin dosage and protocols
- Dose range
- 100–200 mcg per injection
- Dosing
- 1–2 times daily; subject to desensitization within 4 weeks
- Common vials
- 2mg, 5mg
Unlock the dosing protocols
Enter your email to keep reading. It is free, and it opens these sections on every compound page in this browser.
- Dose, route, how often and how long
- A titration schedule
- Beginner, intermediate and advanced protocols
- Reconstitution and handling notes
You also get the free peptide cheat sheet by email. Unsubscribe anytime.
Have an account? Sign in
05Prices
Hexarelin prices
No listings
06Chemistry
Chemistry and structure
- Molecular formula
- C47H58N12O6
- Molecular mass
- 887.05 g/mol
- CAS number
- 140703-51-1
- IUPAC name
- His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2
- Amino acid sequence
- His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2
- Half-life
- ~55 minutes is often quoted, but in Imbimbo 1994 (PMID 7957536) that is the half-life of the growth hormone rise after an IV dose, not of hexarelin itself; hexarelin's own elimination half-life after an IV dose was about 76 minutes in rats (PMID 10611139)
08Questions
Frequently asked questions
What is hexarelin and how does it work?
Hexarelin (also called examorelin) is a potent synthetic hexapeptide growth hormone secretagogue that binds two distinct receptors: GHS-R1a (the ghrelin receptor - drives endogenous GH release) and CD36 (a scavenger receptor on cardiomyocytes - drives cardioprotective effects). In young adults it released about as much GH as GHRP-2 at the same intravenous doses, and more than GHRH (Arvat et al., 1997). It also raises cortisol, prolactin and ACTH, about as much as GHRP-2 does at the same dose (Arvat et al., 1999), and repeated twice-daily use partly blunts its GH response (Rahim et al., 1998). It is not FDA-approved; research use is typically SC injection 100-200 mcg 1-2 times daily in short (4-6 week) cycles.
How is hexarelin different from GHRP-2 or ipamorelin?
All three are GHS-R1a agonists but with different selectivity profiles. In head-to-head studies in young adults, hexarelin and GHRP-2 at the same intravenous doses released similar amounts of GH and raised cortisol, ACTH and prolactin to similar levels (Arvat et al., 1997; Arvat et al., 1999). In swine, ipamorelin released GH without raising ACTH or cortisol beyond GHRH levels (Raun et al., 1998); no human study has compared it with hexarelin. Practical implication: hexarelin for short aggressive 4-6 week phases where peak GH pulse matters; GHRP-2 for medium-duration use; ipamorelin for chronic clean daily use. Hexarelin is uniquely able to bind CD36, which drives its cardioprotective research interest - a property neither GHRP-2 nor ipamorelin share.
What is the best hexarelin dosage?
Standard SC protocol is 100-200 mcg per injection, 1-2 times daily (pre-breakfast and pre-bed), cycled 4-6 weeks on with 2-4 weeks off. Beginners start at 100 mcg once daily (pre-bed only) to assess tolerance before escalating. Intermediate users run 150-200 mcg twice daily. The single-injection ceiling is approximately 200 mcg - above this, receptor saturation prevents additional GH release while cortisol continues to rise proportionally. Hexarelin should not be used continuously longer than 6 weeks because receptor desensitization attenuates GH response and cumulative cortisol/prolactin exposure becomes meaningful. Always dose fasted (2-3 hours after last meal) to avoid glucose/insulin-driven somatostatin blunting of GH release.
Does hexarelin raise cortisol a lot?
It raises cortisol and ACTH: a 2 mcg/kg intravenous dose raised both significantly in 12 healthy volunteers (Korbonits et al., 1995). The rise is not unique to hexarelin. In young adults, GHRP-2 at the same dose raised cortisol and ACTH to similar levels (Arvat et al., 1999), and the lack of a rise with ipamorelin was shown in swine, not people (Raun et al., 1998). Per single dose, this is usually clinically trivial in healthy users. Cumulative chronic exposure matters more - which is why hexarelin is recommended for short 4-6 week cycles rather than continuous long-term use. Users with baseline anxiety, HPA axis concerns, insomnia, or mood disorders should use ipamorelin instead of hexarelin. Cortisol monitoring on labs (baseline and end-of-cycle) is important for hexarelin specifically.
What are hexarelin cardiac effects?
Hexarelin binds CD36, a scavenger receptor expressed on cardiomyocytes and macrophages. Preclinical research in animal models documents reduced infarct size following ischemia-reperfusion insult, improved ventricular contractility in cardiomyopathy models, anti-inflammatory effects at vascular endothelium, and favorable cardiac remodeling after experimental myocardial infarction (Torsello 2003 and subsequent work). These effects are mechanistically independent of the GH/IGF-1 axis - hexarelin produces cardiac protection even when GHS-R1a is blocked. Clinical translation to human cardiac therapy has not occurred; no validated cardiac indication exists. The cardiac research interest is genuine but doesn't support self-experimentation in cardiovascular disease - specialist-supervised research protocols only.
Can hexarelin be stacked with other peptides?
Yes, selectively. The most pharmacologically significant stack is hexarelin + GHRH analog (sermorelin, CJC-1295 no-DAC, or tesamorelin) in the same injection, appropriate for short 4-6 week intensive phases; in healthy men, hexarelin given with GHRH released more GH than either peptide alone (Giustina et al., 1996). Hexarelin also stacks well with BPC-157 and TB-500 for tissue repair during aggressive training cycles, and with testosterone replacement for additive anabolic effects. AVOID stacking hexarelin with other GHS-R1a agonists (GHRP-2, GHRP-6, ipamorelin, MK-677) - they are mechanistically redundant. Also avoid stacking with glucocorticoids, high-dose stimulants, or GLP-1 agonists during active weight loss phases. Hexarelin is the GHS compound most sensitive to bad stacking choices because of the HPA cross-reactivity.
What are the side effects of hexarelin?
Common effects: pronounced facial flushing and warmth post-injection (stronger than other GHRPs), injection site reactions, cortisol elevation, prolactin elevation, intermediate appetite stimulation, and vivid dreams with bedtime dosing. Less common: headache (more frequent than with other GHRPs), mild nausea, transient hypotension with IV administration, fluid retention in first weeks, insulin sensitivity reduction with chronic use. GHRP-2 raises ACTH and cortisol to similar levels at the same dose (Arvat et al., 1999), so these effects are not unique to hexarelin. Long-term theoretical concerns include cumulative cortisol exposure contributing to HPA dysregulation, insulin resistance, and sustained IGF-1 elevation. Short cycling (4-6 weeks) minimizes these concerns significantly.
Is hexarelin legal?
Hexarelin is not FDA-approved for any indication in the United States. It has been studied in European clinical trials for GH deficiency diagnostic testing and cardiac research. Research-grade hexarelin is sold through peptide research suppliers under research-only classification. Users should understand this legal context, source from vendors with third-party purity testing, and ideally work with a practitioner familiar with peptide therapy. Some 503B compounding pharmacies include hexarelin in their offerings for physician-supervised off-label use, though it's less commonly compounded than ipamorelin or GHRP-2. See our best vendors guide for reliable sources and peptide-friendly clinical practices.
Why are hexarelin cycles kept short?
Repeated twice-daily use partly blunts hexarelin's GH response, and a 4-week break restored it in 12 healthy older adults (Rahim and Shalet, 1998); no study has compared this with GHRP-2, GHRP-6 or ipamorelin. Within 4-8 weeks of continuous daily dosing, GH response measurably attenuates - you get smaller GH pulses for the same dose. Dose escalation to overcome this attenuation disproportionately increases cortisol and prolactin exposure rather than restoring GH output. The pharmacologically sensible response is to cycle: 4-6 weeks on, then 2-4 weeks off, allowing the receptor to resensitize. This cycling requirement is why hexarelin is better positioned as a situational short-cycle tool than as a chronic daily compound - ipamorelin or low-dose GHRP-2 are better for continuous long-term GH support.
Should I use hexarelin or ipamorelin for bodybuilding?
Most modern peptide protocols favor ipamorelin for the majority of bodybuilding use cases because: (1) it is expected to hold its GH response over long use, although no published human study of ipamorelin has lasted longer than 7 days (Beck et al., 2014), (2) in swine it did not raise ACTH or cortisol beyond GHRH levels (Raun et al., 1998), (3) it has minimal appetite effect (useful during cutting), and (4) its longer half-life (about 2 hours; the ~55 minutes often quoted for hexarelin is the half-life of its growth hormone response, not of the peptide) provides more sustained coverage. Hexarelin has a legitimate role in short 4-6 week intensive anabolic phases where maximum peak GH pulse matters more than cortisol cleanliness - typically stacked with CJC-1295 no-DAC and testosterone replacement. After a hexarelin phase, transition back to ipamorelin for maintenance and cut phases. Using hexarelin continuously for bodybuilding is a common mistake that produces diminishing GH returns and accumulating cortisol exposure. See ipamorelin for detailed use-case comparison.
Related
Articles on Hexarelin
Free 2026 Peptide Cheat Sheet (PDF)
38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.